UBS Finds Over A Million Americans Using "Unapproved" Compounded GLP-1s

Shares of Danish pharmaceutical giant Novo Nordisk have experienced a sharp sell-off this week after slashing its full-year sales and profit guidance, citing softening Wegovy demand driven by compounded GLP-1 headwinds. If losses hold through Friday, the magnitude of the drawdown will mark the largest weekly decline ever for the stock trading in Copenhagen.

A key question right now among some institutional investors: